New York based securities law firm, Sichenzia Ross Friedman Ference LLP, acted as counsel to New York-based Synergy Pharmaceuticals Inc., a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases, in connection with its recently completed underwritten public offering of common stock pursuant to Synergy’s shelf registration statement. The Company raised an aggregate of $51.75 million, inclusive of the over-allotment option. Aegis Capital Corp. acted as the representative of the underwriters in the offering.
About Sichenzia Ross Friedman Ference LLP
Sichenzia Ross Friedman Ference LLP are corporate and securities lawyers that provide experienced, professional representation in all matters involving the securities industry, as well as in all general corporate and litigation matters. SRFF’s clients range from start-ups to established, listed companies. They include private and public corporations, partnerships, broker-dealers, bank-affiliated broker-dealers, investment advisors, registered personnel, public and corporate customers and investors, partnerships and other entities. SRFF also advises institutional investors on transactions involving complex securities law considerations. SRFF’s practice includes the representation of clients located in the United States and throughout the world.
